Details of the Drug Combination

General Information of Drug Combination (ID: DCVRZZ6)

Drug Combination Name
Docetaxel Mitoxantrone
Indication
Disease Entry Status REF
Prostate Cancer Phase 1 [1]
Component Drugs Docetaxel   DMDI269 Mitoxantrone   DMM39BF
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Docetaxel
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [2]
Breast carcinoma N.A. Approved [2]
Head and neck cancer 2D42 Approved [2]
Leiomyosarcoma 2B58 Approved [2]
Lung cancer 2C25.0 Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Prostate adenocarcinoma N.A. Approved [2]
Prostate cancer 2C82.0 Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Urinary system neoplasm N.A. Approved [2]
Gastric cancer 2B72 Investigative [2]
Docetaxel Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inhibitor [10]
------------------------------------------------------------------------------------
Docetaxel Interacts with 8 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [11]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [12]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [13]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [14]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [15]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [16]
TAP-like protein (ABCB9) DT68UV2 ABCB9_HUMAN Substrate [17]
Multidrug resistance-associated protein 7 (ABCC10) DTPS120 MRP7_HUMAN Substrate [18]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DTP(s)
Docetaxel Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [19]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [20]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [20]
------------------------------------------------------------------------------------
Docetaxel Interacts with 83 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Response To Substance [21]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Increases ADR [22]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Increases Expression [23]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Response To Substance [21]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [24]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [25]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [26]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [26]
Progesterone receptor (PGR) OT0FZ3QE PRGR_HUMAN Decreases Expression [26]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Decreases Expression [26]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Increases Expression [26]
Dihydropyrimidine dehydrogenase (DPYD) OTWRF2NR DPYD_HUMAN Decreases Activity [7]
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) OTBPCU2O TR10A_HUMAN Increases Expression [27]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [27]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Degradation [28]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [29]
PC4 and SFRS1-interacting protein (PSIP1) OT4YAFUS PSIP1_HUMAN Increases Cleavage [30]
RAF proto-oncogene serine/threonine-protein kinase (RAF1) OT51LSFO RAF1_HUMAN Increases Expression [31]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Increases Secretion [32]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [8]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Phosphorylation [33]
Protein kinase C beta type (PRKCB) OTYQ0656 KPCB_HUMAN Increases Phosphorylation [34]
Keratin, type I cytoskeletal 18 (KRT18) OTVLQFIP K1C18_HUMAN Increases Expression [35]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Increases Activity [36]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Decreases Expression [37]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [33]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Decreases Expression [38]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [39]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Increases Expression [40]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Decreases Expression [41]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Decreases Expression [41]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Increases Activity [36]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [42]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [31]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [31]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [9]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [41]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Phosphorylation [43]
Caspase-2 (CASP2) OTUDYSPP CASP2_HUMAN Increases Activity [30]
Cyclin-dependent kinase inhibitor 2A (CDKN2A) OTN0ZWAE CDN2A_HUMAN Decreases Expression [44]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Decreases Expression [24]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [45]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [46]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [8]
Focal adhesion kinase 1 (PTK2) OT3Q1JDY FAK1_HUMAN Increases Cleavage [47]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [48]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Increases Expression [28]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [47]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Activity [28]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Decreases Phosphorylation [28]
ELL-associated factor 2 (EAF2) OTSOET5L EAF2_HUMAN Decreases Expression [41]
Small integral membrane protein 14 (SMIM14) OT47IF19 SIM14_HUMAN Decreases Expression [41]
Protein FAM117A (FAM117A) OT2FBGGV F117A_HUMAN Decreases Expression [41]
Delta-like protein 4 (DLL4) OTRA4K2V DLL4_HUMAN Increases Expression [45]
Tumor necrosis factor receptor superfamily member 19 (TNFRSF19) OTTVT4MB TNR19_HUMAN Decreases Expression [41]
Tropomodulin-2 (TMOD2) OTTTUH2W TMOD2_HUMAN Decreases Expression [41]
Flavin-containing monooxygenase 3 (FMO3) OT1G2EV3 FMO3_HUMAN Affects Response To Substance [49]
Kinesin heavy chain isoform 5A (KIF5A) OT3ETTI6 KIF5A_HUMAN Decreases Response To Substance [50]
Proteinase-activated receptor 1 (F2R) OT4WVWBO PAR1_HUMAN Decreases Response To Substance [51]
ATP-binding cassette sub-family G member 1 (ABCG1) OT5BG6MK ABCG1_HUMAN Affects Response To Substance [49]
Regulator of G-protein signaling 17 (RGS17) OT5RVUDS RGS17_HUMAN Increases Response To Substance [52]
Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (BUB1B) OT8KME51 BUB1B_HUMAN Affects Response To Substance [53]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Response To Substance [54]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Response To Substance [55]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Decreases Response To Substance [56]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Affects Response To Substance [49]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Increases Response To Substance [21]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Increases Response To Substance [57]
Kinesin-like protein KIFC3 (KIFC3) OTOPD4QO KIFC3_HUMAN Decreases Response To Substance [50]
Regulator of G-protein signaling 10 (RGS10) OTQ8N1QH RGS10_HUMAN Increases Response To Substance [52]
E3 ubiquitin-protein ligase CHFR (CHFR) OTRAD2TT CHFR_HUMAN Decreases Response To Substance [58]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Response To Substance [59]
Cell surface glycoprotein MUC18 (MCAM) OTT8XKGE MUC18_HUMAN Decreases Response To Substance [60]
Kinesin-like protein KIF12 (KIF12) OTTALNDD KIF12_HUMAN Decreases Response To Substance [50]
Nucleophosmin (NPM1) OTTBYYT0 NPM_HUMAN Decreases Response To Substance [61]
Flavin-containing monooxygenase 2 (FMO2) OTUJUL9S FMO2_HUMAN Affects Response To Substance [49]
NADPH--cytochrome P450 reductase (POR) OTVIDOCH NCPR_HUMAN Increases Response To Substance [21]
Kinesin-like protein KIF14 (KIF14) OTXHT4JM KIF14_HUMAN Decreases Response To Substance [62]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1) OTXNGZCG MD2L1_HUMAN Affects Response To Substance [53]
Cellular retinoic acid-binding protein 2 (CRABP2) OTY01V9G RABP2_HUMAN Affects Response To Substance [63]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Affects Response To Substance [64]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Affects Response To Substance [49]
ATP-binding cassette sub-family C member 6 (ABCC6) OTZT0LKT MRP6_HUMAN Affects Response To Substance [49]
------------------------------------------------------------------------------------
⏷ Show the Full List of 83 DOT(s)
Indication(s) of Mitoxantrone
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [4]
Adult acute monocytic leukemia N.A. Approved [4]
Leukemia N.A. Approved [4]
Solid tumour/cancer 2A00-2F9Z Approved [5]
Non-hodgkin lymphoma 2B33.5 Phase 1/2 [6]
Metastatic prostate carcinoma N.A. Investigative [4]
Mitoxantrone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [68]
------------------------------------------------------------------------------------
Mitoxantrone Interacts with 5 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [69]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [70]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [70]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [71]
ATP-binding cassette sub-family A member 3 (ABCA3) DT2T6VQ ABCA3_HUMAN Substrate [72]
------------------------------------------------------------------------------------
Mitoxantrone Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Metabolism [73]
------------------------------------------------------------------------------------
Mitoxantrone Interacts with 230 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases Expression [23]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [23]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Expression [74]
Voltage-dependent T-type calcium channel subunit alpha-1G (CACNA1G) OTGKBRE4 CAC1G_HUMAN Decreases Expression [65]
Tyrosine-protein kinase JAK2 (JAK2) OTBIDOOR JAK2_HUMAN Decreases Expression [65]
Sodium channel subunit beta-2 (SCN2B) OTFAHJ38 SCN2B_HUMAN Decreases Expression [65]
LIM domain-binding protein 3 (LDB3) OTGQL1AM LDB3_HUMAN Decreases Expression [65]
Creatine kinase M-type (CKM) OTME0KO7 KCRM_HUMAN Decreases Expression [65]
Glutathione peroxidase 1 (GPX1) OTE2O72Q GPX1_HUMAN Increases Expression [65]
Glycogen phosphorylase, muscle form (PYGM) OTWLVWTV PYGM_HUMAN Decreases Expression [65]
Dystrophin (DMD) OTD21T5J DMD_HUMAN Decreases Expression [65]
Myosin-7 (MYH7) OT4Z9T8N MYH7_HUMAN Decreases Expression [65]
Myosin-6 (MYH6) OT3YNCH1 MYH6_HUMAN Decreases Expression [65]
Troponin T, slow skeletal muscle (TNNT1) OT8PBOAR TNNT1_HUMAN Decreases Expression [65]
Receptor tyrosine-protein kinase erbB-3 (ERBB3) OTRSST0A ERBB3_HUMAN Decreases Expression [65]
Sarcoplasmic reticulum histidine-rich calcium-binding protein (HRC) OTDLEJ4T SRCH_HUMAN Decreases Expression [65]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [65]
Sodium/potassium-transporting ATPase subunit alpha-2 (ATP1A2) OTCF8OWW AT1A2_HUMAN Decreases Expression [65]
Potassium voltage-gated channel subfamily KQT member 1 (KCNQ1) OT8SPJNX KCNQ1_HUMAN Decreases Expression [65]
cAMP-dependent protein kinase catalytic subunit PRKX (PRKX) OTDAC6Z0 PRKX_HUMAN Increases Expression [65]
Myomesin-2 (MYOM2) OTD2UOXW MYOM2_HUMAN Decreases Expression [65]
Inward rectifier potassium channel 2 (KCNJ2) OT2OQEZS KCNJ2_HUMAN Increases Expression [65]
Actin, alpha skeletal muscle (ACTA1) OTOVGLPG ACTS_HUMAN Decreases Expression [65]
Iroquois-class homeodomain protein IRX-4 (IRX4) OT0TV6WK IRX4_HUMAN Decreases Expression [65]
Ankyrin-2 (ANK2) OTWB4R1Y ANK2_HUMAN Decreases Expression [65]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [65]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Expression [65]
Dual specificity protein phosphatase 4 (DUSP4) OT6WAO12 DUS4_HUMAN Increases Expression [65]
Sodium channel protein type 5 subunit alpha (SCN5A) OTGYZWR6 SCN5A_HUMAN Decreases Expression [65]
Protein phosphatase 1 regulatory subunit 3A (PPP1R3A) OTJL9VYP PPR3A_HUMAN Decreases Expression [65]
Caveolae-associated protein 4 (CAVIN4) OTB1DM2C CAVN4_HUMAN Decreases Expression [65]
Nebulin-related-anchoring protein (NRAP) OTO6H3YF NRAP_HUMAN Decreases Expression [65]
Ryanodine receptor 2 (RYR2) OT0PF19E RYR2_HUMAN Decreases Expression [65]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [65]
Histone-lysine N-methyltransferase PRDM16 (PRDM16) OT0BGA27 PRD16_HUMAN Decreases Expression [65]
Voltage-dependent calcium channel subunit alpha-2/delta-2 (CACNA2D2) OTFJXVQQ CA2D2_HUMAN Decreases Expression [65]
Atrial natriuretic peptide-converting enzyme (CORIN) OT4SK7DK CORIN_HUMAN Decreases Expression [65]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Increases Expression [75]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [74]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Decreases Activity [76]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Affects Activity [77]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Activity [78]
Retinoic acid receptor alpha (RARA) OT192V9V RARA_HUMAN Affects Mutagenesis [79]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [74]
Retinoic acid receptor beta (RARB) OT367U3E RARB_HUMAN Increases Expression [80]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [81]
Protein PML (PML) OT6SM2GD PML_HUMAN Affects Mutagenesis [79]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [82]
Caspase-2 (CASP2) OTUDYSPP CASP2_HUMAN Increases Expression [83]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [82]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [82]
Caspase-6 (CASP6) OTXLD3EC CASP6_HUMAN Increases Activity [82]
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Decreases Expression [84]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [66]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Decreases Expression [85]
Beclin-1 (BECN1) OT4X293M BECN1_HUMAN Decreases Expression [85]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [82]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [78]
Autophagy protein 5 (ATG5) OT4T5SMS ATG5_HUMAN Decreases Expression [85]
Regulator of G-protein signaling 2 (RGS2) OT0FSRW7 RGS2_HUMAN Affects Response To Substance [67]
Mitochondrial pyruvate carrier 2 (MPC2) OT0GHXGG MPC2_HUMAN Affects Response To Substance [67]
Molybdenum cofactor sulfurase (MOCOS) OT0TL3Q5 MOCOS_HUMAN Affects Response To Substance [67]
Tripartite motif-containing protein 2 (TRIM2) OT0V1YVC TRIM2_HUMAN Affects Response To Substance [67]
LEM domain-containing protein 2 (LEMD2) OT0YLT7L LEMD2_HUMAN Affects Response To Substance [86]
Iroquois-class homeodomain protein IRX-1 (IRX1) OT0ZN9EJ IRX1_HUMAN Affects Response To Substance [86]
Insulin-like growth factor-binding protein 7 (IGFBP7) OT1D416P IBP7_HUMAN Affects Response To Substance [67]
Methylosome subunit pICln (CLNS1A) OT1HL9L1 ICLN_HUMAN Affects Response To Substance [67]
D-3-phosphoglycerate dehydrogenase (PHGDH) OT1LMRTG SERA_HUMAN Affects Response To Substance [67]
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (MTHFD2) OT1LQSGX MTDC_HUMAN Affects Response To Substance [67]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D) OT1RWFV0 PDE4D_HUMAN Affects Response To Substance [67]
TBC1 domain family member 8 (TBC1D8) OT2011SS TBCD8_HUMAN Affects Response To Substance [67]
Protein FAM117A (FAM117A) OT2FBGGV F117A_HUMAN Affects Response To Substance [67]
Protein transport protein Sec31A (SEC31A) OT2U42AC SC31A_HUMAN Affects Response To Substance [67]
DNA-binding protein SATB2 (SATB2) OT2W80XC SATB2_HUMAN Affects Response To Substance [67]
Large neutral amino acids transporter small subunit 1 (SLC7A5) OT2WPVXD LAT1_HUMAN Affects Response To Substance [67]
Very long chain fatty acid elongase 5 (ELOVL5) OT375W1Z ELOV5_HUMAN Affects Response To Substance [86]
Nuclear receptor subfamily 4 group A member 2 (NR4A2) OT3F9IR2 NR4A2_HUMAN Affects Response To Substance [67]
Solute carrier organic anion transporter family member 4A1 (SLCO4A1) OT3J1G7H SO4A1_HUMAN Affects Response To Substance [67]
Fatty acid CoA ligase Acsl3 (ACSL3) OT3MWER1 ACSL3_HUMAN Affects Response To Substance [67]
Leucine-rich repeat transmembrane protein FLRT3 (FLRT3) OT3XMZU3 FLRT3_HUMAN Affects Response To Substance [67]
ELAV-like protein 4 (ELAVL4) OT3YH6J6 ELAV4_HUMAN Affects Response To Substance [86]
Angiomotin-like protein 1 (AMOTL1) OT40G45S AMOL1_HUMAN Affects Response To Substance [86]
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A (PDE8A) OT4RF9Z4 PDE8A_HUMAN Affects Response To Substance [67]
PRELI domain containing protein 3B (PRELID3B) OT4TRT4K PLD3B_HUMAN Affects Response To Substance [67]
Argininosuccinate synthase (ASS1) OT4ZMG0Q ASSY_HUMAN Affects Response To Substance [67]
DNA topoisomerase 1 (TOP1) OT51O0CF TOP1_HUMAN Increases ADR [87]
Centrosomal protein 15 (CEP15) OT52961J CEP15_HUMAN Affects Response To Substance [67]
Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial (OXCT1) OT536PE7 SCOT1_HUMAN Affects Response To Substance [67]
Ubiquitin-like protein ISG15 (ISG15) OT53QQ7N ISG15_HUMAN Affects Response To Substance [67]
cAMP-responsive element-binding protein-like 2 (CREBL2) OT58JBNU CRBL2_HUMAN Affects Response To Substance [67]
PACRG-like protein (PACRGL) OT5DEP0X PACRL_HUMAN Affects Response To Substance [86]
Isocitrate dehydrogenase subunit alpha, mitochondrial (IDH3A) OT5QQB5L IDH3A_HUMAN Affects Response To Substance [67]
G antigen 6 (GAGE6) OT5WRC1N GAGE6_HUMAN Affects Response To Substance [67]
Melanoma-associated antigen D1 (MAGED1) OT6EOLFC MAGD1_HUMAN Affects Response To Substance [67]
Laminin subunit beta-1 (LAMB1) OT6J9LJR LAMB1_HUMAN Affects Response To Substance [67]
Glutathione peroxidase 3 (GPX3) OT6PK94R GPX3_HUMAN Affects Response To Substance [67]
Band 4.1-like protein 2 (EPB41L2) OT6UABPM E41L2_HUMAN Affects Response To Substance [86]
Monocarboxylate transporter 7 (SLC16A6) OT7BIIZX MOT7_HUMAN Affects Response To Substance [67]
Homeobox protein engrailed-2 (EN2) OT7EZCM2 HME2_HUMAN Affects Response To Substance [67]
Exosome complex exonuclease RRP44 (DIS3) OT7UPHJS RRP44_HUMAN Affects Response To Substance [67]
Protein LBH (LBH) OT87AT1X LBH_HUMAN Affects Response To Substance [67]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Increases ADR [87]
Secreted frizzled-related protein 4 (SFRP4) OT8PQUVB SFRP4_HUMAN Affects Response To Substance [86]
Mesoderm-specific transcript homolog protein (MEST) OT8Q4U8Y MEST_HUMAN Affects Response To Substance [67]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Affects Response To Substance [67]
Exostosin-like 2 (EXTL2) OT8U672K EXTL2_HUMAN Affects Response To Substance [67]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Affects Response To Substance [67]
Frizzled-2 (FZD2) OT952ML1 FZD2_HUMAN Affects Response To Substance [67]
Transcription factor MafF (MAFF) OT9B7MX0 MAFF_HUMAN Affects Response To Substance [86]
Pyridoxal phosphate homeostasis protein (PLPBP) OT9DZ8P6 PLPHP_HUMAN Affects Response To Substance [67]
Splicing factor 45 (RBM17) OT9ROJCL SPF45_HUMAN Decreases Response To Substance [88]
Coxsackievirus and adenovirus receptor (CXADR) OT9ZP02A CXAR_HUMAN Affects Response To Substance [67]
RING finger and CHY zinc finger domain-containing protein 1 (RCHY1) OTAE7504 ZN363_HUMAN Affects Response To Substance [67]
Transgelin (TAGLN) OTAEZ0KP TAGL_HUMAN Affects Response To Substance [67]
POM121 and ZP3 fusion protein (POMZP3) OTAH2JOK POZP3_HUMAN Affects Response To Substance [67]
Transmembrane protein 47 (TMEM47) OTAJ4CPX TMM47_HUMAN Affects Response To Substance [67]
RCC1 and BTB domain-containing protein 1 (RCBTB1) OTAYELI8 RCBT1_HUMAN Affects Response To Substance [67]
Collagen alpha-1(XI) chain (COL11A1) OTB0DRMS COBA1_HUMAN Affects Response To Substance [67]
Stearoyl-CoA desaturase (SCD) OTB1073G SCD_HUMAN Affects Response To Substance [67]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) OTB97VIK IF2B3_HUMAN Affects Response To Substance [67]
Cochlin (COCH) OTBEHD89 COCH_HUMAN Affects Response To Substance [67]
Epoxide hydrolase 1 (EPHX1) OTBKWQER HYEP_HUMAN Increases ADR [87]
Spondin-1 (SPON1) OTC06MY4 SPON1_HUMAN Affects Response To Substance [67]
Interferon regulatory factor 7 (IRF7) OTC1A2PQ IRF7_HUMAN Affects Response To Substance [67]
Cocaine esterase (CES2) OTC647SQ EST2_HUMAN Affects Response To Substance [67]
Mothers against decapentaplegic homolog 2 (SMAD2) OTC6VB4K SMAD2_HUMAN Affects Response To Substance [67]
Cystathionine gamma-lyase (CTH) OTC90LA0 CGL_HUMAN Affects Response To Substance [67]
KRR1 small subunit processome component homolog (KRR1) OTCMJ3K3 KRR1_HUMAN Affects Response To Substance [67]
Early growth response protein 1 (EGR1) OTCP6XGZ EGR1_HUMAN Affects Response To Substance [67]
Interferon-stimulated gene 20 kDa protein (ISG20) OTCWRJJW ISG20_HUMAN Affects Response To Substance [67]
Tropomyosin alpha-1 chain (TPM1) OTD73X6R TPM1_HUMAN Affects Response To Substance [67]
Spondin-2 (SPON2) OTE7JLNM SPON2_HUMAN Affects Response To Substance [67]
Interferon-induced transmembrane protein 1 (IFITM1) OTECO1G8 IFM1_HUMAN Affects Response To Substance [67]
Syndecan-2 (SDC2) OTEEHY1D SDC2_HUMAN Affects Response To Substance [67]
Schwannomin-interacting protein 1 (SCHIP1) OTF3FR4A SCHI1_HUMAN Affects Response To Substance [67]
NADH dehydrogenase iron-sulfur protein 5 (NDUFS5) OTF40UYJ NDUS5_HUMAN Affects Response To Substance [67]
G antigen 7 (GAGE7) OTF8BTR9 GAGE7_HUMAN Affects Response To Substance [67]
Dehydrogenase/reductase SDR family member 2, mitochondrial (DHRS2) OTFHWIY8 DHRS2_HUMAN Affects Response To Substance [67]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Decreases Response To Substance [89]
Laminin subunit alpha-2 (LAMA2) OTFROQWE LAMA2_HUMAN Affects Response To Substance [86]
Squalene synthase (FDFT1) OTGDISIT FDFT_HUMAN Affects Response To Substance [67]
Double-stranded RNA-specific editase 1 (ADARB1) OTGKSZEV RED1_HUMAN Affects Response To Substance [67]
Chordin-like protein 1 (CHRDL1) OTGMWVVA CRDL1_HUMAN Affects Response To Substance [67]
Cytotoxic granule associated RNA binding protein TIA1 (TIA1) OTGPN3P8 TIA1_HUMAN Affects Response To Substance [67]
Voltage-gated potassium channel subunit beta-2 (KCNAB2) OTH115IE KCAB2_HUMAN Affects Response To Substance [67]
Nidogen-2 (NID2) OTHC33FF NID2_HUMAN Affects Response To Substance [67]
Endothelial lipase (LIPG) OTHEE942 LIPG_HUMAN Affects Response To Substance [67]
Chemokine-like factor (CKLF) OTHLPHA0 CKLF_HUMAN Affects Response To Substance [67]
E3 ubiquitin-protein ligase MYCBP2 (MYCBP2) OTHODA1F MYCB2_HUMAN Affects Response To Substance [67]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Affects Response To Substance [67]
Basal cell adhesion molecule (BCAM) OTHZOPSD BCAM_HUMAN Affects Response To Substance [67]
Melanoma-associated antigen 6 (MAGEA6) OTI8S0O2 MAGA6_HUMAN Affects Response To Substance [67]
Laminin subunit gamma-1 (LAMC1) OTIG527N LAMC1_HUMAN Affects Response To Substance [67]
Leucine-rich repeat-containing G-protein coupled receptor 4 (LGR4) OTIMWEK5 LGR4_HUMAN Affects Response To Substance [67]
Lysosomal acid lipase/cholesteryl ester hydrolase (LIPA) OTIOLNHE LICH_HUMAN Affects Response To Substance [67]
Runt-related transcription factor 3 (RUNX3) OTITK1XD RUNX3_HUMAN Affects Response To Substance [67]
Lymphocyte function-associated antigen 3 (CD58) OTIUGMGS LFA3_HUMAN Affects Response To Substance [67]
Insulin-like growth factor-binding protein 3 (IGFBP3) OTIX63TX IBP3_HUMAN Affects Response To Substance [67]
Nuclear receptor-interacting protein 1 (NRIP1) OTIZOJQV NRIP1_HUMAN Affects Response To Substance [67]
Protein S100-P (S100P) OTJCXNJG S100P_HUMAN Affects Response To Substance [67]
Ectoderm-neural cortex protein 1 (ENC1) OTJEUB6U ENC1_HUMAN Affects Response To Substance [67]
Transcriptional activator Myb (MYB) OTJH64IV MYB_HUMAN Increases ADR [87]
Trefoil factor 3 (TFF3) OTJJDRTU TFF3_HUMAN Affects Response To Substance [67]
Antigen peptide transporter 1 (TAP1) OTJL27PW TAP1_HUMAN Affects Response To Substance [90]
Calcium/calmodulin-dependent protein kinase II inhibitor 1 (CAMK2N1) OTKCR5XL CK2N1_HUMAN Affects Response To Substance [67]
Aldehyde dehydrogenase, mitochondrial (ALDH2) OTKJ9I3N ALDH2_HUMAN Affects Response To Substance [67]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Affects Response To Substance [67]
CUGBP Elav-like family member 2 (CELF2) OTLJJ4VT CELF2_HUMAN Affects Response To Substance [67]
Protein CASC3 (CASC3) OTLK3K4U CASC3_HUMAN Affects Response To Substance [86]
Tyrosine-protein kinase Fyn (FYN) OTLSLVZS FYN_HUMAN Affects Response To Substance [67]
Peroxiredoxin-2 (PRDX2) OTLWCY9T PRDX2_HUMAN Affects Response To Substance [67]
Homeobox protein Hox-A5 (HOXA5) OTLWGPQD HXA5_HUMAN Affects Response To Substance [67]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) OTM0GDTP IF2A_HUMAN Affects Response To Substance [67]
Dual specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2) OTMDVWPS DYRK2_HUMAN Affects Response To Substance [67]
Copper-transporting ATPase 1 (ATP7A) OTMR3GXP ATP7A_HUMAN Decreases Response To Substance [91]
Neurofilament heavy polypeptide (NEFH) OTMSCW5I NFH_HUMAN Affects Response To Substance [67]
Death-associated protein kinase 1 (DAPK1) OTNCNUCO DAPK1_HUMAN Affects Response To Substance [67]
Protein phosphatase inhibitor 2 (PPP1R2) OTNLOUQR IPP2_HUMAN Affects Response To Substance [67]
HMG box transcription factor BBX (BBX) OTNQ3QUC BBX_HUMAN Affects Response To Substance [67]
1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon (AGPAT5) OTNY3VMD PLCE_HUMAN Affects Response To Substance [67]
Melanoma-associated antigen D4 (MAGED4B) OTO37U7W MAGD4_HUMAN Affects Response To Substance [67]
Beta-secretase 2 (BACE2) OTO5YQVK BACE2_HUMAN Affects Response To Substance [67]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Decreases Response To Substance [92]
Receptor-type tyrosine-protein phosphatase epsilon (PTPRE) OTOD5NID PTPRE_HUMAN Affects Response To Substance [67]
Probable serine carboxypeptidase CPVL (CPVL) OTOJL31C CPVL_HUMAN Affects Response To Substance [67]
Caveolae-associated protein 3 (CAVIN3) OTOLBK79 CAVN3_HUMAN Affects Response To Substance [67]
Ecotropic viral integration site 5 protein homolog (EVI5) OTOPAP55 EVI5_HUMAN Affects Response To Substance [67]
Pre-B-cell leukemia transcription factor 1 (PBX1) OTORABGO PBX1_HUMAN Affects Response To Substance [67]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Decreases Response To Substance [93]
GTP cyclohydrolase 1 (GCH1) OTOZ6NSL GCH1_HUMAN Affects Response To Substance [67]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 (PLCB4) OTPA0QHW PLCB4_HUMAN Affects Response To Substance [67]
G antigen 4 (GAGE4) OTPB5C0O GAGE4_HUMAN Affects Response To Substance [67]
Interleukin-13 receptor subunit alpha-2 (IL13RA2) OTPC2G0X I13R2_HUMAN Affects Response To Substance [67]
Tribbles homolog 1 (TRIB1) OTPEO17G TRIB1_HUMAN Affects Response To Substance [67]
Tumor protein D52 (TPD52) OTPKSK43 TPD52_HUMAN Affects Response To Substance [67]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C) OTPL0AI1 ABC3C_HUMAN Affects Response To Substance [67]
Eukaryotic translation initiation factor 5A-1 (EIF5A) OTQ8DJX5 IF5A1_HUMAN Affects Response To Substance [67]
Clusterin (CLU) OTQGG0JM CLUS_HUMAN Affects Response To Substance [67]
Histone deacetylase 4 (HDAC4) OTQNGD32 HDAC4_HUMAN Affects Response To Substance [67]
Tissue-type plasminogen activator (PLAT) OTQPDNAB TPA_HUMAN Affects Response To Substance [67]
3-oxo-5-alpha-steroid 4-dehydrogenase 1 (SRD5A1) OTQRET2B S5A1_HUMAN Affects Response To Substance [67]
Sal-like protein 2 (SALL2) OTQWI68Q SALL2_HUMAN Affects Response To Substance [67]
G antigen 2A (GAGE2A) OTRAJ80C GAG2A_HUMAN Affects Response To Substance [67]
Actin, gamma-enteric smooth muscle (ACTG2) OTRDWUO0 ACTH_HUMAN Affects Response To Substance [67]
DNA endonuclease RBBP8 (RBBP8) OTRHJ3GI CTIP_HUMAN Affects Response To Substance [67]
Cysteine/serine-rich nuclear protein 2 (CSRNP2) OTRZNC1C CSRN2_HUMAN Affects Response To Substance [86]
Heat shock-related 70 kDa protein 2 (HSPA2) OTSDET7B HSP72_HUMAN Affects Response To Substance [67]
Guanylate cyclase soluble subunit beta-1 (GUCY1B1) OTSHPHVB GCYB1_HUMAN Affects Response To Substance [67]
Bone marrow stromal antigen 2 (BST2) OTU4LCJV BST2_HUMAN Affects Response To Substance [67]
Synaptotagmin-like protein 2 (SYTL2) OTUIOWKL SYTL2_HUMAN Affects Response To Substance [86]
Max-interacting protein 1 (MXI1) OTUQ9E0D MXI1_HUMAN Affects Response To Substance [67]
Fibronectin type-III domain-containing protein 3A (FNDC3A) OTUX3S2I FND3A_HUMAN Affects Response To Substance [67]
HLA class II histocompatibility antigen, DR beta 5 chain (HLA-DRB5) OTUX5TWM DRB5_HUMAN Affects Response To Substance [67]
Prolyl 4-hydroxylase subunit alpha-1 (P4HA1) OTV04QE5 P4HA1_HUMAN Affects Response To Substance [67]
Forkhead box protein F2 (FOXF2) OTV20NGX FOXF2_HUMAN Affects Response To Substance [67]
Nicotinamide phosphoribosyltransferase (NAMPT) OTVJR3GL NAMPT_HUMAN Affects Response To Substance [67]
Poly polymerase tankyrase-1 (TNKS) OTVOUTPX TNKS1_HUMAN Affects Response To Substance [67]
ADP-ribose glycohydrolase MACROD1 (MACROD1) OTWFEVRW MACD1_HUMAN Affects Response To Substance [67]
Sorbin and SH3 domain-containing protein 1 (SORBS1) OTWH8762 SRBS1_HUMAN Affects Response To Substance [67]
S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) OTX8L3M5 SAHH2_HUMAN Affects Response To Substance [67]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Affects Response To Substance [94]
Ras-related GTP-binding protein D (RRAGD) OTXLVWAH RRAGD_HUMAN Affects Response To Substance [86]
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related (HMG20B) OTY94WRA HM20B_HUMAN Affects Response To Substance [67]
Bone morphogenetic protein 7 (BMP7) OTYATP2K BMP7_HUMAN Affects Response To Substance [67]
Glutamine synthetase (GLUL) OTYGTCGF GLNA_HUMAN Affects Response To Substance [67]
Complement decay-accelerating factor (CD55) OTZ3HWTO DAF_HUMAN Affects Response To Substance [67]
BTB/POZ domain-containing protein 3 (BTBD3) OTZ607YT BTBD3_HUMAN Affects Response To Substance [67]
Zinc finger protein PLAGL1 (PLAGL1) OTZAO900 PLAL1_HUMAN Affects Response To Substance [67]
Ras GTPase-activating protein 1 (RASA1) OTZJ3LP4 RASA1_HUMAN Affects Response To Substance [86]
Ras GTPase-activating-like protein IQGAP1 (IQGAP1) OTZRWTGA IQGA1_HUMAN Affects Response To Substance [67]
------------------------------------------------------------------------------------
⏷ Show the Full List of 230 DOT(s)

References

1 ClinicalTrials.gov (NCT00017563) Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
2 Docetaxel FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6809).
4 Mitoxantrone FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7242).
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer. 2006 Aug 15;119(4):783-91.
8 Induction of tubulin by docetaxel is associated with p53 status in human non small cell lung cancer cell lines. Int J Cancer. 2006 Jan 15;118(2):317-25. doi: 10.1002/ijc.21372.
9 Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer. 2005 Jun 20;115(3):484-92. doi: 10.1002/ijc.20878.
10 Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
11 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
12 Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
13 Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010 Aug 10;103(4):560-6.
14 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
15 FDA Drug Development and Drug Interactions
16 Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.
17 RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel. Mol Biosyst. 2017 Sep 26;13(10):2125-2134.
18 Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
19 Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol. 2005 Feb 20;23(6):1061-9.
20 Drug Interactions Flockhart Table
21 Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
22 Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008 May;99(5):967-72.
23 Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer. 2004 Sep 10;111(4):484-93. doi: 10.1002/ijc.20230.
24 Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
25 Comparison of burst of reactive oxygen species and activation of caspase-3 in apoptosis of K562 and HL-60 cells induced by docetaxel. Cancer Lett. 2004 Oct 8;214(1):103-13. doi: 10.1016/j.canlet.2004.03.047.
26 Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers. Clin Cancer Res. 2004 Dec 15;10(24):8163-9.
27 Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 2001 Jan 15;61(2):759-63.
28 Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res. 2007 Feb 15;13(4):1308-14. doi: 10.1158/1078-0432.CCR-06-2216.
29 PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010 Sep;66(4):765-71. doi: 10.1007/s00280-009-1221-4. Epub 2009 Dec 30.
30 Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol Cancer. 2009 Aug 28;8:68. doi: 10.1186/1476-4598-8-68.
31 Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells. Front Biosci. 2005 Sep 1;10:2566-75. doi: 10.2741/1720.
32 Kaempferol and quercetin stimulate granulocyte-macrophage colony-stimulating factor secretion in human prostate cancer cells. Mol Cell Endocrinol. 2008 Jun 11;287(1-2):57-64. doi: 10.1016/j.mce.2008.01.015. Epub 2008 Feb 3.
33 All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene. 2004 Jan 15;23(2):426-33. doi: 10.1038/sj.onc.1207040.
34 Docetaxel Facilitates Endothelial Dysfunction through Oxidative Stress via Modulation of Protein Kinase C Beta: The Protective Effects of Sotrastaurin. Toxicol Sci. 2015 May;145(1):59-67. doi: 10.1093/toxsci/kfv017. Epub 2015 Jan 28.
35 Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer. 2006 Jun 5;94(11):1592-8. doi: 10.1038/sj.bjc.6603129.
36 The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 2004 Jan;3(1):59-70.
37 Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010 Oct 15;70(20):7992-8002. doi: 10.1158/0008-5472.CAN-10-0585. Epub 2010 Aug 31.
38 Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. Biochem Pharmacol. 2011 Nov 1;82(9):1100-9. doi: 10.1016/j.bcp.2011.07.078. Epub 2011 Jul 23.
39 Replication-dependent -H2AX formation is involved in docetaxel-induced apoptosis in NSCLC A549 cells. Oncol Rep. 2010 Nov;24(5):1297-305. doi: 10.3892/or_00000986.
40 Docetaxel induced cardiotoxicity. Heart. 2001 Aug;86(2):219. doi: 10.1136/heart.86.2.219.
41 Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
42 [The mechanism of docetaxel-induced apoptosis in human lung cancer cells]. Zhonghua Zhong Liu Za Zhi. 2000 May;22(3):208-11.
43 Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. J Nutr Biochem. 2015 Apr;26(4):408-15. doi: 10.1016/j.jnutbio.2014.11.017. Epub 2015 Jan 15.
44 Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
45 Role of delta-like ligand-4 in chemoresistance against docetaxel in MCF-7 cells. Hum Exp Toxicol. 2017 Apr;36(4):328-338. doi: 10.1177/0960327116650006. Epub 2016 Jun 22.
46 Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance. Chem Biol Interact. 2021 May 1;340:109448. doi: 10.1016/j.cbi.2021.109448. Epub 2021 Mar 26.
47 Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8829-36. doi: 10.1158/1078-0432.CCR-05-1728.
48 Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy. J Oral Pathol Med. 2005 Feb;34(2):93-9. doi: 10.1111/j.1600-0714.2004.00257.x.
49 Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. OMICS. 2013 Jul;17(7):353-67. doi: 10.1089/omi.2013.0019. Epub 2013 Jun 11.
50 Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer. Breast Cancer Res Treat. 2012 Feb;131(3):849-58. doi: 10.1007/s10549-011-1500-8. Epub 2011 Apr 9.
51 PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem. 2005 Oct 15;96(3):641-52. doi: 10.1002/jcb.20533.
52 Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells. Mol Cancer. 2010 Nov 2;9:289. doi: 10.1186/1476-4598-9-289.
53 Mitotic checkpoint genes, hsMAD2 and BubR1, in oesophageal squamous cancer cells and their association with 5-fluorouracil and cisplatin-based radiochemotherapy. Clin Oncol (R Coll Radiol). 2008 Oct;20(8):639-46. doi: 10.1016/j.clon.2008.06.010. Epub 2008 Aug 8.
54 EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1). Arch Toxicol. 2015 Apr;89(4):591-605. doi: 10.1007/s00204-014-1275-x. Epub 2014 Jun 3.
55 [Antisense RNA targeting survivin enhances the chemosensitivity of LOVO/Adr cells to taxotere]. Zhonghua Wei Chang Wai Ke Za Zhi. 2005 Sep;8(5):455-8.
56 Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. doi: 10.1089/ars.2013.5295. Epub 2013 Nov 14.
57 HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat. 2004 Aug;86(3):197-206. doi: 10.1023/B:BREA.0000036783.88387.47.
58 Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol. 2007 Oct;31(4):713-20.
59 Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res. 2005 May-Jun;25(3c):2367-79.
60 CD146 expression in human breast cancer cell lines induces phenotypic and functional changes observed in Epithelial to Mesenchymal Transition. PLoS One. 2012;7(8):e43752. doi: 10.1371/journal.pone.0043752. Epub 2012 Aug 30.
61 Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
62 KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. Neoplasia. 2014 Mar;16(3):247-56, 256.e2. doi: 10.1016/j.neo.2014.03.008.
63 The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-induced apoptosis in breast invasive carcinoma: A pan-cancer analysis. Chem Biol Interact. 2023 Mar 1;373:110372. doi: 10.1016/j.cbi.2023.110372. Epub 2023 Feb 2.
64 Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther. 2008 Jan;7(1):19-26. doi: 10.1158/1535-7163.MCT-07-0557. Epub 2008 Jan 9.
65 Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Arch Toxicol. 2016 Nov;90(11):2763-2777.
66 Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leuk Lymphoma. 2004 Jul;45(7):1429-36. doi: 10.1080/1042819042000198858.
67 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
68 Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
69 Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol. 2006 Apr;69(4):1499-505.
70 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
71 Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
72 A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33.
73 FDA label of Mitoxantrone. The 2020 official website of the U.S. Food and Drug Administration.
74 High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood. 1993 Nov 15;82(10):3133-40.
75 [Alteration of expression of survivin in HL-60 cells treated with chemotherapeutic drugs]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Apr;14(2):347-50.
76 Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening. Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4929-34. doi: 10.1073/pnas.0812308106. Epub 2009 Mar 2.
77 Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
78 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
79 Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood. 2010 Jan 14;115(2):326-30. doi: 10.1182/blood-2009-07-235051. Epub 2009 Nov 2.
80 The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells. Differentiation. 2007 Nov;75(9):883-90. doi: 10.1111/j.1432-0436.2007.00199.x. Epub 2007 Jul 2.
81 Single pre-treatment with hypericin, a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells. Toxicol In Vitro. 2014 Oct;28(7):1259-73. doi: 10.1016/j.tiv.2014.06.011. Epub 2014 Jun 30.
82 Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol. 2003 Sep 1;66(5):711-24. doi: 10.1016/s0006-2952(03)00410-6.
83 Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol Cancer Res. 2004 Jan;2(1):53-61.
84 Dynamic coregulatory complex containing BRCA1, E2F1 and CtIP controls ATM transcription. Cell Physiol Biochem. 2012;30(3):596-608. doi: 10.1159/000341441. Epub 2012 Jul 27.
85 Autophagy (but not metabolism) is a key event in mitoxantrone-induced cytotoxicity in differentiated AC16 cardiac cells. Arch Toxicol. 2023 Jan;97(1):201-216. doi: 10.1007/s00204-022-03363-6. Epub 2022 Oct 10.
86 Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene. 2005 Nov 17;24(51):7542-51. doi: 10.1038/sj.onc.1208908.
87 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
88 Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005 Aug 1;65(15):6593-600. doi: 10.1158/0008-5472.CAN-03-3675.
89 A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol Cancer Ther. 2008 Feb;7(2):263-70. doi: 10.1158/1535-7163.MCT-07-0445.
90 Gene expressions associated with chemosensitivity in human hepatoma cells. Hepatogastroenterology. 2007 Mar;54(74):489-92.
91 Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res. 2007 May 15;67(10):4860-8. doi: 10.1158/0008-5472.CAN-06-3096.
92 Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochim Biophys Sin (Shanghai). 2011 Aug;43(8):647-53. doi: 10.1093/abbs/gmr050. Epub 2011 Jun 28.
93 Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res. 2007 Jun 15;67(12):5831-9. doi: 10.1158/0008-5472.CAN-06-4533.
94 Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther. 2005 Jan;12(1):90-100. doi: 10.1038/sj.cgt.7700775.